A double blind study of vitamin B6 in Down's syndrome infants. Part 1--Clinical and biochemical results.
Nineteen patients with Down's syndrome participated in a double blind study of the clinical effects of pharmacological doses of vitamin B6 administration, starting under 8 weeks of age and continuing until 3 years of age. Ten patients received the vitamin and nine the placebo. In Part 1 of this study, no statistically significant differences were found between the two groups in mental age, height, weight, cranial circumference or tongue protrusion. A study of side effects conducted on a larger open population found vitamin B6 to be relatively safe when administered over long periods of time with photosensitive blisters as the major complication.
Coleman
M
M
Sobel
S
S
Bhagavan
H N
HN
Coursin
D
D
Marquardt
A
A
Guay
M
M
Hunt
C
C
D001768:Blister / Q000139:chemically induced; D001827:Body Height / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004314:Down Syndrome / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007223:Infant; D007360:Intelligence / Q000187:drug effects; D008297:Male; D011736:Pyridoxine / Q000009:adverse effects / Q000627:therapeutic use*; D012886:Skull / Q000187:drug effects; D014061:Tongue Habits
D011736:Pyridoxine